#Italy #Milan #Parkinson's #Newronika #deep brain stimulation

Newronika Secures Major Funding to Propel Innovative DBS Solutions

Newronika, a frontrunner in the field of advanced deep brain stimulation (DBS), has announced a remarkable milestone with the completion of its €13.6 million Series B financing round. The investment was predominantly driven by a new partner, Fondazione ENEA Tech e Biomedical, and included participation from established investors such as Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. This substantial financial boost is set to significantly advance Newronika’s adaptive DBS system, which is engineered for tailored therapy aimed at alleviating symptoms and minimizing side effects for individuals suffering from Parkinson's disease.

The funds from this financing will not only support the continued clinical validation and market launch of the proprietary system but also assist in expanding product development pipelines, attracting top-tier talent, and fostering strategic partnerships. Newronika's commitment to enhancing its position at the crossroads of neuroscience and medical device engineering has been further validated by their recent achievements, including a grant from The Michael J. Fox Foundation and FDA Investigational Device Exemption approval.

Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika, expressed his excitement about the strong backing from both new and existing investors, stating, "This Series B funding validates our dedication to revolutionizing deep brain stimulation practices. We are focused on seamlessly integrating real-time neural data with machine learning to create highly personalized treatment solutions that go beyond the existing market offerings."

The vital capabilities of Newronika's adaptive DBS platform promise to transform treatment modalities for movement disorders globally. As articulated by ENEA Tech e Biomedical’s General Manager, Maria Cristina Porta, the collaboration emphasizes a shared vision for supporting groundbreaking medical technologies that enhance patient care while fostering innovation.

Indaco’s CEO, Davide Turco, reaffirmed their commitment to Newronika, highlighting the potential of its adaptive DBS system to significantly improve the quality of life for many patients with Parkinson's disease. Claudio Giuliano, Chairman of Newronika, remarked that the successful completion of this Series B funding is pivotal in solidifying the company’s strategic vision for the future.

About Newronika and Its Innovation

Newronika is revolutionizing the landscape of deep brain stimulation through its adaptive platform, which utilizes real-time patient data for optimizing therapeutic interventions. Headquartered in Milan, Italy, Newronika is poised at the forefront of innovations for neurological disorders, engaging in ongoing research partnerships and backed by a CE Mark and FDA Investigational Device Exemption indication.

For further details on Newronika’s pioneering initiatives, visit their website or connect with them on LinkedIn.

About the Investors

• - Fondazione ENEA Tech e Biomedical: This Italian foundation champions high-impact projects across biotechnology, medical devices, and life sciences with a focus on transformative healthcare solutions.
• - Indaco Venture Partners SGR: A prominent Italian venture capital firm, Indaco is dedicated to supporting innovative healthcare and technology enterprises.
• - Innogest SGR: Specializing in med-tech and digital health investments, Innogest draws on its broad expertise to promote promising startups in the healthcare arena.
• - Wille Finance: A Swiss multi-family office, Wille Finance is engaged in impactful healthcare, technology, and transformative sector investments.
• - TNBT Capital: Based in Paris, TNBT Capital focuses on advancing pioneering technologies within the neuromodulation landscape.
• - F3F: An Italian venture firm investing in innovative medical technology companies focused on enhancing patient care.